Annogen enters Contract Manufacturing market: AIM™ services and SuRE™ promoters
The AIM™ service, introduced in 2022 for cell therapy development, is now also available to the contract manufacturing market for virus and recombinant protein manufacturing.
VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters
VectorY Therapeutics and Annogen signed a Research Collaboration for the identification of CNS-cell specific synthetic promoters for VectorY’s vectorized antibody programs.
Annogen Announces Research Project with Pfizer to TestNon-coding Genetic Sequences
Annogen has begun a research project with Pfizer to functionally test tens of thousands of disease-related non-coding sequence variants for their effect on gene regulation.
Annogen introduces AIM™ service
A new service to identify gene insertions and assess their expression levels for >100,000 integrations in parallel.
SuRE technology finds hidden gene regulation
Many diseases are determined by differences in yet undiscovered gene regulation. Thanks to plasmids and ‘barcodes’, the SuRE assay can map this for the entire human genome.
Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company.
Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and non-coding sequence variants.
Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.
Annogen BV was incorporated with exclusive rights to commercialize the SuRE technology outside the gene therapy field, for drug discovery, pharmacogenomics, cell therapy and agricultural biotechnology.
